百利天恒自主研发的iza-bren治疗EGFR突变肺癌的一项研究客观缓解率达100%

Group 1 - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. announced that its self-developed drug, iza-bren (EGFR×HER3 dual antibody ADC), has been recognized at the 2025 World Lung Cancer Conference (WCLC) with two research results selected for the official press program [2] - The phase II study results of iza-bren combined with Osimertinib for patients with locally advanced or metastatic EGFR mutation non-small cell lung cancer (NSCLC) were presented by Professor Zhou Fei from the Eastern Hospital of Tongji University, involving 154 patients [2] - Among the 40 patients receiving the 2.5 mg/kg D1D8Q3W dose of iza-bren combined with Osimertinib, the objective response rate (ORR) reached 100%, with a progression-free survival (PFS) rate of 92.1% and overall survival (OS) rate of 94.8% at 12 months [3] Group 2 - A separate study led by Professor Fang Wenfeng from Sun Yat-sen University Cancer Center on the monotherapy of iza-bren for patients with locally advanced or metastatic EGFR mutation NSCLC showed a median PFS of 12.5 months and a tumor shrinkage rate of 94% among 50 patients previously treated with EGFR-TKI [3] - The ongoing phase III studies for both combination and monotherapy of iza-bren are being conducted globally and in China, with the first patient already dosed in the registration phase [3]